A less pronounced increase in the mDC1/pDC ratio at the third month of methimazole treatment suggests a more essential role of the shifts between CD141+ mDC2 and CD303+ pDC than CD1c+ mDC1 over the course of Graves’ disease management. Here, CLEC4C is linked to Graves disease.